| 发明名称 | Screening method | ||
| 摘要 | This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient. | ||
| 申请公布号 | US9347103(B2) | 申请公布日期 | 2016.05.24 |
| 申请号 | US201414306137 | 申请日期 | 2014.06.16 |
| 申请人 | ISIS Innovation Limited | 发明人 | La Thangue Nicholas B.;Fotheringham Susan |
| 分类号 | C12Q1/68;C12N15/11;G01N33/50;G01N33/574 | 主分类号 | C12Q1/68 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A method of diagnosing the susceptibility of an individual suffering from cancer to treatment with an HDAC inhibitor, the method comprising assessing the level of expression or activity of a gene's expression product in a sample from a patient and comparing said level of expression or activity to a reference, wherein a level of expression or activity that is different to said reference is indicative of an altered susceptibility to treatment with the HDAC inhibitor relative to the reference state, wherein said gene is hHRAD23B (human rad 23B), wherein the expression product is a protein, and wherein the protein is detected by an antibody that binds specifically to the hHRAD23B protein, and wherein the sample comprises tumor cells. | ||
| 地址 | Oxford GB | ||